Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1/2 9Phase 1 5Phase NA 4Phase EARLY_PHASE1 1

Status

Completed 10Terminated 5Unknown 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Plasma cell 1Myeloid 1Gynecologic 1

Conditions

Preleukemia 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Graft vs Host Disease 1Fallopian Tube Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 85Gemcitabine 81Carboplatin 62fludarabine 61Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 49Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 33Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26Pemetrexed 25atezolizumab 24Oxaliplatin 24Capecitabine 24fludarabine phosphate 22Filgrastim 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Alemtuzumab × Clear all
NCT03132584 2019-01-14

Cyclophosphamide and Alemtuzumab In Lymphoma

Dana-Farber Cancer Institute

Phase 1 Terminated
3 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00637390 2016-12-02

A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

University of Michigan Rogel Cancer Center

Phase 1 Terminated
3 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00943293 2014-03-17

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

University of Chicago

Phase 1 Terminated
1 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Lymphoma, Myeloproliferative Disorders, Preleukemia, Neoplasms, Plasma Cell

NCT00113048 2014-02-05

Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

Sanofi

Phase 1 Terminated
24 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT00947388 2013-08-22

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Case Comprehensive Cancer Center

Phase 1 Terminated
9 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡